Table 3.
Immunological characteristics of DSA+ patients.
| ABMR+ | ABMR- | p-value | |
|---|---|---|---|
| Number of patients | 35 | 28 | |
| Number of DSA | |||
| 1 | 22 [63%] | 20 [71%] | 0.47 |
| 2 | 3 [9%] | 3 [11%] | 0.77 |
| 3 | 2 [6%] | 2 [7%] | 0.82 |
| 4 or more | 8 [23%] | 3 [11%] | 0.21 |
| HLA Class | |||
| Class I | 11 [31%] | 15 [54%] | 0.08 |
| Class II | 15 [43%] | 9 [32%] | 0.38 |
| Class I and II | 9 [26%] | 4 [14%] | 0.27 |
| Class immunodominant DSA | |||
| Class I | 18 [51%] | 17 [61%] | 0.46 |
| Class II | 17 [49%] | 11 [39%] | 0.46 |
| MFI immunodominant DSA | |||
| Median [IQR] | 4016 [2504-9031] | 5705 [3031-11069] | 0.44 |
| <5000 | 21 [60%] | 12 [46%] | 0.28 |
| >5000 | 14 [40%] | 14 [54%] | 0.28 |
| OL MFI >8000 or LC MFI >3000 | 12 [43%] | 12 [34%] | 0.49 |
| Sum of MFI | |||
| Median | 6141 [2974-11456] | 6469 [3481-12418] | 0.58 |
| <10.000 | 23 [68%] | 17 [65%] | 0.85 |
| >10.000 | 11 [32%] | 9 [35%] | 0.85 |
| SAB testing kit | |||
| LifeCodes | 15 [56%] | 13 [56%] | 0.94 |
| OneLambda | 12 [44%] | 10 [44%] | 0.94 |
| Flow-crossmatch | |||
| Flow + | 11 [31%] | 9 [32%] | 0.54 |
| Flow – | 19 [54%] | 13 [46%] | 0.95 |
| No flow result | 5 [14%] | 6 [21%] | 0.46 |
| Origin of DSA | |||
| RMM | 12 [34%] | 7 [25%] | 0.43 |
| Pregnancy | 10 [29%] | 6 [21%] | 0.52 |
| Male, no RMM | 5 [14%] | 6 [21%] | 0.46 |
| RMM and pregnancy | 0 [0%] | 1 [4%] | – |
| Female, no RMM or HLA-typed pregnancy | 7 [20%] | 8 [29%] | 0.43 |
DSA, donor-specific antibody; MFI, mean fluorescent intensity; flow, flowcytometric crossmatch; SAB, single antigen bead; RMM, repeated mismatch; OL, OneLambda; LC, LifeCodes.